NEWS RELEASE
Pacific Biosciences Names Michael W. Hunkapiller Chief
Executive Officer
MENLO PARK, Calif. - January 6, 2012 - Pacific Biosciences of
California, Inc. (NASDAQ:PACB), provider of Single Molecule
Real Time (SMRT®) sequencing products, today
announced the appointment of Michael W. Hunkapiller, Ph.D.,
as President and Chief Executive Officer effective
immediately. He succeeds Hugh Martin, who will remain on the
Board of Directors through the company's next annual meeting
of shareholders.
Dr. Hunkapiller was named Executive Chairman of PacBio's
Board of Directors in October 2011. Dr. Hunkapiller spent 21
years of his career helping build Applied Biosystems ("ABI,"
now part of Life Technologies Inc.) into a market leader in
the life sciences industry. From 1995 to 2004
he served as ABI's President and General Manager. In 2004 he
joined Alloy Ventures as a
General Partner, and in 2005 led Alloy's investment in PacBio
and joined the company's Board of Directors. Dr. Hunkapiller
will continue to represent Alloy Ventures as a Director of
NuGEN, Verinata Health and RainDance Technologies.
"I am excited and honored to take on the role of President
and CEO of PacBio," said Dr. Hunkapiller. "Since joining the
company's Board, I have always believed that our SMRT
technology would play a significant role in biological
research and the advancement of medical therapies. Now that
we have begun to deliver products to customers, I am more
convinced than ever that we are on our way to fulfilling that
promise. The company is in great position with the people,
products, and cash to drive the adoption of its disruptive
technology."
Bill Ericson, PacBio's lead independent Board Member and Mohr
Davidow General Partner commented: "We are thankful for
Hugh's dedication and efforts in transforming PacBio from an
early stage R&D company to a leader in single molecule
technology. Mike brings unmatched expertise, experience and
relationships with customers in the life science tools market
and is uniquely qualified to lead the company through its
next stage of growth."
Mr. Martin commented: "Developing a technology as advanced as
single molecule sequencing was a tremendous achievement for
PacBio, and Mike is now the ideal person to drive the broader
adoption of PacBio's products. I am in support of this
decision and am looking forward to identifying my next
exciting career venture."
For more
information about Pacific Biosciences, please visit www.pacificbiosciences.com
. You can also follow
the company on Twitter www.twitter.com/pacbio.
About Pacific Biosciences
Pacific Biosciences' mission is to transform the way
humankind acquires, processes and interprets data from living
systems through the design, development and commercialization
of innovative
tools for biological research. The company has developed a
novel approach to studying the synthesis and regulation of
DNA, RNA and proteins. Combining recent advances in
nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific
Biosciences has created a powerful technology platform called
single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of
biomolecules with single molecule resolution, which has the
potential to transform the understanding of biological
systems by providing a window into these systems that has not
previously been open for scientific study.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements may contain
words such as "believe," "may,"
"estimate," "anticipate,"
"continue," "intend," "expect,"
"plan," the negative of these terms, or other
similar expressions, and include the assumptions that
underlie such statements. Such statements include, but are
not limited to, statements regarding the
Company's SMRT technology and the Company's growth. These
statements are subject to known and unknown risks and
uncertainties that could cause actual results to differ
materially
from those expressed or implied by such statements, including
but not limited to risks discussed from time to time in
documents Pacific Biosciences of California, Inc. has filed
with the
Securities and Exchange Commission, including the risks
identified under the section captioned "Risk
Factors" in its recently filed Quarterly Report on Form
10-Q. All forward-looking statements are based on estimates,
projections and assumptions as of the date hereof.
Pacific
Biosciences undertakes no obligation to update any
forward-looking statements.
Media:
Nicole Litchfield
For Pacific Biosciences
415-793-6468 nicole@bioscribe.com
Investors:
Trevin Rard
Pacific Biosciences
650-521-8450
ir@pacificbiosciences.com
distribué par | Ce noodl a été diffusé par Pacific Biosciences of California Inc. et initialement mise en ligne sur le site http://www.pacificbiosciences.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-06 18:51:14 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer |